The price trend for Inovio Pharmaceuticals (INO) has been bearish lately and the stock has lost 6.9% over the past two weeks.
Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired ...
Inovio Pharmaceuticals Inc INO shares are trading higher on Friday morning after the company reported fourth-quarter results ...
Inovio Pharmaceuticals (NASDAQ:INO) management used the company’s fourth-quarter and full-year 2025 earnings call to detail ...
Inovio Pharmaceuticals Inc (INO) navigates financial hurdles and regulatory uncertainties while advancing its DNA medicine ...
This forgotten stock might be too risky even for contrarian investors.
What are the allegations? Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device According to the complaint, ...
Shares of Inovio Pharmaceuticals Inc. INO slipped 2.48% to $1.57 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index COMP falling ...
(INO) on Thursday reported fourth-quarter profit of $3.8 million.
Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S.
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (INO) ...
Q4 2025 Earnings Call March 12, 2026 4:30 PM EDTCompany ParticipantsJennie WillsonJacqueline Shea - CEO, President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results